Generi Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Generi Biotech is an established, revenue-generating European biotech firm operating in the diagnostics and life sciences tools sector. Its core business is built on three pillars: proprietary CE-marked IVD real-time PCR kits for pharmacogenetics and genetic disorders, a comprehensive portfolio of life sciences reagents and custom oligo synthesis, and specialized CRO testing services under GLP/GMP standards. The company serves a diverse clientele including clinical labs, research institutions, and pharmaceutical developers, leveraging its EU-based manufacturing and R&D to cater to both regional and global markets through a distributor network.

PharmacogeneticsGenetic Disorders

Technology Platform

Proprietary real-time PCR (qPCR) assay design and manufacturing, custom oligonucleotide synthesis (including specialized probes), and GLP/GMP-compliant testing services for biodistribution and viral vector analysis.

Opportunities

The global shift towards personalized medicine and pharmacogenetics drives demand for its specialized IVD kits.

Expansion of its distributor network worldwide presents a significant growth lever for its product lines.

The booming gene therapy sector creates a substantial service opportunity for its niche GMP/GLP testing capabilities in biodistribution and viral vector analysis.

Risk Factors

The company faces substantial regulatory risk from the complex and costly transition to the new EU IVDR, which could disrupt sales of its core IVD products.

It operates in highly competitive markets dominated by large multinational corporations, posing challenges on price and scale.

There may be customer concentration risk in its home Central European region, requiring successful international expansion to mitigate.

Competitive Landscape

Generi Biotech competes in the molecular diagnostics space against global giants like Roche, Thermo Fisher Scientific, and Qiagen, and in oligonucleotides against firms like Eurofins Genomics and Integrated DNA Technologies. Its differentiation lies in its EU-based manufacturing, niche pharmacogenetic focus, and integrated service model. In the CRO testing niche for advanced therapies, it competes with specialized preclinical CROs, leveraging its GMP/GLP facilities.

More companies in Diagnostics & Precision Medicine →More companies in Czech Republic →